Diseases / Atherosclerosis
Atherosclerosis
DiseaseAtherosclerosis is a chronic inflammatory arterial disease characterized by lipid-rich plaque buildup in vessel walls, leading to atherosclerotic cardiovascular disease. It underlies major events such as myocardial infarction, ischemic stroke, and peripheral arterial disease.
- Trials
- 1472
- Recruiting
- 130
- Completed
- 879
- With results
- 194
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 3 | — | — | — | 8 | 1 | — | — | 2 | — | 14 |
| Phase 1 | 4 | — | — | — | 47 | 4 | 1 | — | 4 | — | 60 |
| Phase 1/2 | 2 | — | — | — | 8 | 1 | 1 | — | 5 | — | 17 |
| Phase 2 | 7 | 5 | — | 4 | 79 | 3 | 4 | — | 7 | — | 109 |
| Phase 2/3 | 1 | — | — | — | 18 | 2 | — | — | 7 | — | 28 |
| Phase 3 | 12 | 1 | — | 9 | 81 | 8 | — | — | 10 | — | 121 |
| Phase 4 | 13 | 2 | — | 3 | 89 | 23 | 5 | — | 41 | — | 176 |
| Not applicable | 41 | 8 | 2 | 14 | 202 | 13 | 16 | 1 | 66 | — | 363 |
| Unknown | 47 | 22 | 7 | 25 | 347 | 16 | 10 | 2 | 107 | 1 | 584 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Atherosclerosis | 14 | 60 | 17 | 109 | 28 | 121 | 176 | 363 | 584 | 1472 |
| Cardiovascular Diseases | 2 | 9 | 5 | 23 | 5 | 20 | 26 | 62 | 199 | 351 |
| Coronary Artery Disease | — | 4 | 1 | 22 | 7 | 11 | 31 | 70 | 116 | 262 |
| Heart Diseases | — | — | — | 7 | — | 9 | 4 | 12 | 106 | 138 |
| Inflammation | 2 | 7 | 3 | 16 | 4 | 5 | 21 | 25 | 40 | 123 |
| Coronary Disease | — | 2 | 2 | 6 | — | 12 | 14 | 12 | 71 | 119 |
| Peripheral Arterial Disease | 2 | 5 | 3 | 2 | 3 | 12 | 11 | 41 | 19 | 98 |
| Diabetes Mellitus | 1 | 3 | — | 4 | 4 | 7 | 7 | 20 | 46 | 92 |
| Stroke | — | 1 | — | 2 | 1 | 8 | 8 | 14 | 54 | 88 |
| Myocardial Infarction | — | 1 | — | 2 | 2 | 10 | 5 | 15 | 48 | 83 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | National Heart, Lung, and Blood Institute (NHLBI) | 91 | 6 |
| 2 | GlaxoSmithKline | 32 | 3 |
| 3 | Novartis Pharmaceuticals | 22 | 8 |
| 4 | Boston Scientific Corporation | 20 | 3 |
| 5 | Massachusetts General Hospital | 20 | 0 |
| 6 | AstraZeneca | 16 | 5 |
| 7 | Korea University | 15 | 0 |
| 8 | Organon and Co | 14 | 4 |
| 9 | Assistance Publique - Hôpitaux de Paris | 12 | 2 |
| 10 | Abbott Medical Devices | 11 | 2 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Atorvastatin | 44 |
| 2 | Rosuvastatin Calcium | 37 |
| 3 | Ezetimibe | 33 |
| 4 | Aspirin | 31 |
| 5 | Simvastatin | 29 |
| 6 | ALN-PCS | 21 |
| 7 | darapladib | 20 |
| 8 | Clopidogrel | 18 |
| 9 | Exercise | 17 |
| 10 | Niacin | 16 |
Evidence
- Results reported
- 22.1%194 of 879 completed
- Published
- 15.7%138 of 879 completed
- Primary endpoint met
- 59.1%110 of 186 analyses
- Median months to report
- 17
Documents disclosed
Trial profile
- Median enrollment
- 120
- Median duration
- 36months
- Countries
- 84
- Study sites
- 14904
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 46
- Phase 1
- 34
- Phase 1/2
- 53
- Phase 2
- 113
- Phase 2/3
- 120
- Phase 3
- 340
- Phase 4
- 100
- Not applicable
- 90
- Unknown
- 244
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | New York | United States | 72 |
| 2 | Seoul | South Korea | 66 |
| 3 | Beijing | China | 64 |
| 4 | Boston | United States | 64 |
| 5 | Houston | United States | 63 |
| 6 | Baltimore | United States | 56 |
| 7 | Bethesda | United States | 56 |
| 8 | Los Angeles | United States | 53 |
| 9 | Dallas | United States | 51 |
| 10 | Jacksonville | United States | 48 |
Terminations
- Terminated
- 71
- Withdrawn
- 37
- Suspended
- 3
- Stopped for recruitment
- 1.4%20 of 1472 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT05977413 Withdrawn | Withdrawn | The trial was never started because it was not funded. | 2032-06-30 |
| NCT06852560 Withdrawn | Withdrawn | PI has left institution | 2026-11-30 |
| NCT05720156 Withdrawn | Withdrawn | Lack of Feasibility | 2026-03-31 |
| NCT07693712 Terminated | Terminated | Staffing challenges and subsequent withdrawal of funding. | 2026-02-26 |
| NCT05468957 Withdrawn | Withdrawn | Initiating PI left our institution. | 2025-07-31 |
| NCT06280976 Withdrawn | Withdrawn | study withdrawn, no participants enrolled, changes in the study design planned | 2025-01-01 |
| NCT05834673 Terminated | Terminated | Loss of strategic interest by the funding party. The participants' recruitment rate failed to meet the target within the pre-specified recruitment windows. | 2024-12-19 |
| NCT05575245 Withdrawn | Withdrawn | The research fund has not yet arrived. | 2024-10-20 |
| NCT05699915 Terminated | Terminated | Study was stopped due to negative preliminary analysis, slow recruitment (105 patients over 2,5 years), lack of funding, need for more centers, and the changing treatment landscape (approval of ICIs in combination with other cancer treatments). | 2024-07-12 |
| NCT04282161 Withdrawn | Withdrawn | Business Decision | 2024-02-29 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: